Vectura Appoints Sharon Johnson Executive VP

Published on: 

Inhalation drug delivery company Vectura announces new organizational structure to drive innovation, customer focus, and growth.

Vectura Group plc, a United Kingdom-based provider of inhaled drug delivery services, has named Sharon Johnson as executive vice-president for delivery management. In this newly created role, Johnson will focus on helping customer acquisition, program management, and regulatory medical affairs, the company reported in a Feb. 10, 2020 announcement.

Johnson has more than 30 years of experience in the pharmaceutical industry, including previous positions at Catalent, GE Healthcare’s Medical Diagnostic Division, Baxter Healthcare, and Sanofi Aventis. She holds a postgraduate diploma in industrial pharmaceutical studies with distinction from Brighton University and a bachelor’s Honors degree in biological sciences/microbiology from North East Surrey College of

“Sharon has built an enviable reputation as an exceptional leader in the pharmaceutical services space and has a strong track record of transformational leadership, talent development, and execution excellence,” said Will Downie, Vectura CEO, in the press statement. “Our new structure will support growth and sharpen our focus on working with our clients to bring more inhalation medicines to market.”


 “Having spent my entire career in the healthcare arena, it is a true privilege to join Vectura, a company with such a rich scientific heritage in the inhalation space,” said Johnson in the press statement. “I look forward to working with my colleagues on the executive leadership team and wider business to help combine deep science and agile processes that will accelerate the development of new and exciting inhaled medicines for patients.”

Source: Vectura